Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China.
Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Hainan University, Haikou, 570200, China.
Nat Commun. 2024 Nov 29;15(1):10382. doi: 10.1038/s41467-024-54854-2.
Proteolytic targeting chimera (PROTAC) technology is a protein-blocking technique and induces antitumor effects, with potential advantages. However, its effect is limited by insufficient distribution and accumulation in tumors. Herein, a transformable nanomedicine (dBET6@CFMPD) with mitochondrial targeting capacity is designed and constructed to combine PROTAC with photodynamic therapy (PDT). In this work, we demonstrate that dBET6@CFMPD exhibits great biodistribution and retention, and can induce potent antitumor response to suppress primary and metastatic tumors, becoming a nanomedicine with potential in cancer combination therapy.
蛋白水解靶向嵌合体（PROTAC）技术是一种阻断蛋白的技术，可诱导抗肿瘤作用，具有潜在优势。然而，其效果受到在肿瘤中分布和积累不足的限制。本研究设计并构建了一种具有线粒体靶向能力的可变形纳米药物（dBET6@CFMPD），将 PROTAC 与光动力疗法（PDT）相结合。在这项工作中，我们证明了 dBET6@CFMPD 具有很好的体内分布和保留特性，并能引发强烈的抗肿瘤反应，抑制原发性和转移性肿瘤，成为癌症联合治疗中具有潜力的纳米药物。
